Hoffmann A, Reinhardt M, Rechenbach C, Henschel L, Jorke D
Institut für Klinische Pharmakologie, Friedrich-Schiller-Universität Jena.
Gastroenterol J. 1989;49(1):8-11.
In 17 patients who more than 1 year ago had suffered from a dihydralazine induced hepatitis the biotransformation velocity was investigated and compared with a healthy control group. 15 out of the 17 patients and 5 out of the 10 volunteers are slow acetylators. All slow acetylators eliminate sulfamethazine more slowly than rapid acetylators.--The elimination of caffeine and metamizol--test substances for oxidative biotransformation reactions--was retarded in patients after dihydralazine induced hepatitis in comparison to control persons. Slow acetylators have to be controlled carefully because of their higher risk of dihydralazine induced drug hepatitis.
在17名1年多前曾患肼屈嗪诱发肝炎的患者中，研究了其生物转化速度，并与健康对照组进行了比较。17名患者中有15名以及10名志愿者中有5名是慢乙酰化者。所有慢乙酰化者消除磺胺二甲嘧啶的速度均比快乙酰化者慢。——与对照组相比，肼屈嗪诱发肝炎患者体内咖啡因和安乃近（氧化生物转化反应的测试物质）的消除有所延迟。由于慢乙酰化者患肼屈嗪诱发药物性肝炎的风险较高，因此必须对其进行密切监测。
